Header Logo

Connection

Leslie Shaw to Kidney Transplantation

This is a "connection" page, showing publications Leslie Shaw has written about Kidney Transplantation.
Connection Strength

2.083
  1. Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation. 2010 Jul 15; 90(1):31-7.
    View in: PubMed
    Score: 0.284
  2. Kaplan B, Gaston RS, Meier-Kriesche HU, Bloom RD, Shaw LM. Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. Ther Drug Monit. 2010 Apr; 32(2):224-7.
    View in: PubMed
    Score: 0.278
  3. van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005 Oct 15; 80(2 Suppl):S244-53.
    View in: PubMed
    Score: 0.204
  4. Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001 Feb; 34(1):17-22.
    View in: PubMed
    Score: 0.148
  5. Shaw LM, Korecka M, Aradhye S, Grossman R, Bayer L, Innes C, Cucciara A, Barker C, Naji A, Nicholls A, Brayman K. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000 Jun; 40(6):624-33.
    View in: PubMed
    Score: 0.141
  6. Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, Morris RE, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P, Morris RG. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem. 1998 Jul; 31(5):317-22.
    View in: PubMed
    Score: 0.123
  7. Shaw LM. Mycophenolate mofetil: pharmacokinetic strategies for optimizing immunosuppression. Drug Metabol Drug Interact. 1997; 14(1):33-40.
    View in: PubMed
    Score: 0.111
  8. Shaw LM, Annesley T, Gilmore B, Brayman K. Measurement of OG37-325 by high-performance liquid chromatography. Transplant Proc. 1994 Oct; 26(5):3010-2.
    View in: PubMed
    Score: 0.095
  9. Shaw LM, Audet PR, Grossman RA, Fields L, Lensmeyer GL, Dafoe DC. Adjustment of cyclosporine dosage in renal transplant patients based on concentration measured specifically in whole blood: clinical outcome results and diagnostic utility. Transplant Proc. 1990 Jun; 22(3):1267-73.
    View in: PubMed
    Score: 0.070
  10. de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn. 2009 Dec; 36(6):541-64.
    View in: PubMed
    Score: 0.068
  11. Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009 Jul; 9(7):1607-19.
    View in: PubMed
    Score: 0.066
  12. van Hest RM, van Gelder T, Vulto AG, Shaw LM, Mathot RA. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2009; 48(7):463-76.
    View in: PubMed
    Score: 0.064
  13. Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw LM, Munir L, Ulbricht B, Cooper M. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation. 2008 Mar 27; 85(6):821-6.
    View in: PubMed
    Score: 0.061
  14. Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit. 2000 Feb; 22(1):27-30.
    View in: PubMed
    Score: 0.034
  15. Kaplan B, Meier-Kriesche HU, Friedman G, Mulgaonkar S, Gruber S, Korecka M, Brayman KL, Shaw LM. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol. 1999 Jul; 39(7):715-20.
    View in: PubMed
    Score: 0.033
  16. Oellerich M, Armstrong VW, Sch?tz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem. 1998 Jul; 31(5):309-16.
    View in: PubMed
    Score: 0.031
  17. Shaw LM, Korecka M, van Breeman R, Nowak I, Brayman KL. Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. Clin Biochem. 1998 Jul; 31(5):323-8.
    View in: PubMed
    Score: 0.031
  18. Schulman SL, Shaw LM, Jabs K, Leonard MB, Brayman KL. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. Transplantation. 1998 May 27; 65(10):1397-8.
    View in: PubMed
    Score: 0.031
  19. Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998 Mar; 38(3):268-75.
    View in: PubMed
    Score: 0.030
  20. Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem. 1998 Feb; 44(2):381-7.
    View in: PubMed
    Score: 0.030
  21. Weber M, Deng S, Arenas J, Aradhye S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy. Transplant Proc. 1997 Dec; 29(8):3669-70.
    View in: PubMed
    Score: 0.030
  22. Salm P, Taylor PJ, Clark A, Balderson GA, Grygotis A, Norris RL, Lynch SV, Shaw LM, Pond SM. High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants. Ther Drug Monit. 1997 Dec; 19(6):694-700.
    View in: PubMed
    Score: 0.030
  23. Weber M, Ketchum RJ, Sellers M, Aradhye S, Deng S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients. Transplant Proc. 1997 Feb-Mar; 29(1-2):338-9.
    View in: PubMed
    Score: 0.028
  24. Heifets M, Cooney GF, Shaw LM, Libetti G. Diurnal variation of cyclosporine clearance in stable renal transplant recipients receiving continuous infusion. Transplantation. 1995 Dec 27; 60(12):1615-7.
    View in: PubMed
    Score: 0.026
  25. Cooney GF, Heifets M, Bell A, Shaw LM, LiBetti G. Utility of pretransplantation cyclosporine pharmacokinetic studies. Ther Drug Monit. 1994 Apr; 16(2):151-4.
    View in: PubMed
    Score: 0.023
  26. Shipkova M, Niedmann PD, Armstrong VW, Sch?tz E, Wieland E, Shaw LM, Oellerich M. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem. 1998 Jul; 44(7):1481-8.
    View in: PubMed
    Score: 0.008
  27. Holt DW, Johnston A, Marsden JT, Vernillet L, Keown PA, Rosano TG, Shaw LM, Rosenthaler J. Monoclonal antibodies for radioimmunoassay of cyclosporine: a multicenter comparison of their performance with the Sandoz polyclonal radioimmunoassay kit. Clin Chem. 1988 Jun; 34(6):1091-6.
    View in: PubMed
    Score: 0.004
  28. Kahn GC, Shaw LM, Kane MD. Routine monitoring of cyclosporine in whole blood and in kidney tissue using high performance liquid chromatography. J Anal Toxicol. 1986 Jan-Feb; 10(1):28-34.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.